Abstract: A sterilizable particle-size reduction apparatus, component parts thereof and a method of sterilizing and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Abstract: The present invention provides a process for handling ?9-THC, which comprises preparing a solution of ?9-THC in a solvent which exists as a gas at room temperature and atmospheric pressure. The invention also provides solutions of ?9-THC in the solvent and solid preparations of ?9-THC.

Abstract: A sterilizable particle-size reduction apparatus, component parts thereof and a method of sterilizing and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Abstract: A compound of formula (I) wherein R is selected from (i) a 5 to 7 membered heterocyclic ring containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, which is optionally substituted by one or more groups independently selected from halo, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy and phenyl; (ii) (C1-C6)alkyl, which is optionally substituted by one or more substituents each independently selected from halo, oxo, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy and phenyl; (iii) (C1-C6)alkyl substituted by (C3-C13)cycloalkyl, which is optionally substituted by one or more substituents each independently selected from halo, oxo, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy and phenyl; and (iv) (C3-C13)cycloalkyl, which is optionally substituted by one or more substituents each independently selected from halo, oxo, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy and phenyl.

Abstract: ?9 THC is obtained by extracting ?9 THC and ?9 THC carboxylic acid from plant material using a non-polar solvent and decarboxylating the ?9 THC acid into ?9 THC in the same solvent, without a solvent swap, in the presence of aqueous base. The ?9 THC is then washed to remove inorganic impurities, still in the same original solvent.

Abstract: A process for the syntheses of 17?-hydroxy-7?-methyl-19-nor-17?-pregn-5(10)-ene-20-yne-3-one (tibolone, 11) and intermediates useful for the synthesis thereof.

Abstract: A sterilisable particle-size reduction apparatus, component parts thereof and a method of sterilising and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Abstract: A sterilisable particle-size reduction apparatus, component parts thereof and a method of sterilising and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Abstract: A sterilisable particle-size reduction apparatus, component parts thereof and a method of sterilising and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Abstract: The present invention provides a process for handling ?9-THC, which comprises preparing a solution of ?9-THC in a solvent which exists as a gas at room temperature and atmospheric pressure. The invention also provides solutions of ?9-THC in the solvent and solid preparations of ?9-THC.

Abstract: A sterilisable particle-size reduction apparatus, component parts thereof and a method of sterilising and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Abstract: A sterilisable particle-size reduction apparatus, component parts thereof and a method of sterilising and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Abstract: A sterilisable particle-size reduction apparatus, component parts thereof and a method of sterilizing and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Abstract: The present invention provides isolated, purified ?9 THC. In another embodiment, the invention provides pharmaceutical compositions comprising isolated, purified ?9 THC and a pharmaceutically acceptable carrier. In another embodiment, the invention provides methods of preparing pharmaceutical compositions comprising isolated, purified ?9 THC and a pharmaceutically acceptable carrier.

Abstract: ?9 THC acid is obtained from plant material and extracted into an aqueous solvent under conditions of pH control. The acid is converted to a salt and the salt extracted into a polar solvent, yielding acid of high purity. The ?9 THC acid is then converted to ?9 THC which is further purified and combined with a carrier for pharmaceutical use.

Abstract: ?9 THC acid is obtained from plant material and extracted into an aqueous solvent under conditions of pH control. The acid is converted to a salt and the salt extracted into a polar solvent, yielding acid of high purity. The ?9 THC acid is then converted to ?9 THC which is further purified and combined with a carrier for pharmaceutical use.

Abstract: Disclosed are processes for the synthesis and purification of prostaglandins and analogues thereof, especially analogues of PGF2?.

Abstract: A method of preparing cabergoline Form I, comprising forming a solvate including cabergoline and a p-disubstituted benzene of formula (A) or 1,3,5-trimethylbenzene and obtaining cabergoline Form I from the solvate. Another aspect of the present invention provides a method for preparing cabergoline Form I comprising dissolving cabergoline in p-disubstituted benzene or 1,3,5-trimethylbenzene and recovering the cabergoline Form I polymorph, suitably by direct crystallization of Form I or by recovery of a solvate which can be converted to Form I. Another aspect of the present invention provides a novel cabergoline polymorph designated cabergoline Form FB and a method of preparing said polymorph by dissolving or forming a solvate of cabergoline in fluorobenzene and recovering cabergoline Form FB.

Abstract: Disclosed are processes for the synthesis and purification of prostaglandins and analogues thereof, especially analogues of PGF2?.

Abstract: The present application relates to a novel polymorphic form of cabergoline comprising cabergoline and t-amyl methyl ether, designated Form TAME cabergoline, together with a novel method of producing cabergoline.